Format

Send to

Choose Destination
See comment in PubMed Commons below
J Hematol Oncol. 2014 Apr 16;7:34. doi: 10.1186/1756-8722-7-34.

The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression.

Author information

1
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. ruth1626@hotmail.com.

Abstract

Expression of CD44 splice isoforms has been previously reported to correlate with inferior outcomes in DLBCL patients treated with CHOP therapy. However, it is unclear whether this observation remains valid in the R-CHOP era. In this study, we correlated CD44H and CD44v6 status with survival outcomes among DLBCL patients with an emphasis on the comparison between CHOP- and R-CHOP-treated subgroups. Our results suggest that rituximab has significantly decreased the prognostic value of CD44H. We also observed that the therapeutic benefit of rituximab is largely restricted to CD44H-positive cases in this cohort.

PMID:
24739401
PMCID:
PMC4022142
DOI:
10.1186/1756-8722-7-34
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center